JP2010540562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540562A5 JP2010540562A5 JP2010527249A JP2010527249A JP2010540562A5 JP 2010540562 A5 JP2010540562 A5 JP 2010540562A5 JP 2010527249 A JP2010527249 A JP 2010527249A JP 2010527249 A JP2010527249 A JP 2010527249A JP 2010540562 A5 JP2010540562 A5 JP 2010540562A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- indole
- carboxylate
- quinuclidin
- heptan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 25
- 239000012453 solvate Substances 0.000 claims 25
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 208000024827 Alzheimer disease Diseases 0.000 claims 16
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 12
- 206010012289 Dementia Diseases 0.000 claims 12
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 12
- 208000010877 cognitive disease Diseases 0.000 claims 12
- 208000028698 Cognitive impairment Diseases 0.000 claims 8
- 208000028017 Psychotic disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- -1 Quinuclidin-4-ylmethyl 1H-indole-3-carboxylate Chemical compound 0.000 claims 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- IHPXOQDYLTYWAR-UHFFFAOYSA-N (3-oxo-1-azabicyclo[2.2.2]octan-4-yl)methyl 1h-indole-3-carboxylate Chemical compound C1=CC=C2C(C(OCC34CCN(CC3)CC4=O)=O)=CNC2=C1 IHPXOQDYLTYWAR-UHFFFAOYSA-N 0.000 claims 5
- SEDHPUZKCQBANK-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 1h-indole-3-carboxylate Chemical compound C1=CC=C2C(C(OCC34CCN(CC3)C4)=O)=CNC2=C1 SEDHPUZKCQBANK-UHFFFAOYSA-N 0.000 claims 5
- AMLBBMMFMLVCAJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 5-(difluoromethoxy)-1h-indole-3-carboxylate Chemical compound C12=CC(OC(F)F)=CC=C2NC=C1C(=O)OCC1(C2)CCN2CC1 AMLBBMMFMLVCAJ-UHFFFAOYSA-N 0.000 claims 5
- YNUMJLHUOOGLJA-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 5-chloro-1h-indole-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2NC=C1C(=O)OCC1(C2)CCN2CC1 YNUMJLHUOOGLJA-UHFFFAOYSA-N 0.000 claims 5
- QZAHPOTXRJLXFT-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 5-fluoro-1h-indole-3-carboxylate Chemical compound C12=CC(F)=CC=C2NC=C1C(=O)OCC1(C2)CCN2CC1 QZAHPOTXRJLXFT-UHFFFAOYSA-N 0.000 claims 5
- BYCMSLAAWXLXLI-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 5-methoxy-1h-indole-3-carboxylate Chemical compound C12=CC(OC)=CC=C2NC=C1C(=O)OCC1(C2)CCN2CC1 BYCMSLAAWXLXLI-UHFFFAOYSA-N 0.000 claims 5
- OUCGTTDCRABIMA-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 6-(difluoromethoxy)-1h-indole-3-carboxylate Chemical compound FC(F)OC1=CC=C2C(C(=O)OCC34CCN(CC3)C4)=CNC2=C1 OUCGTTDCRABIMA-UHFFFAOYSA-N 0.000 claims 5
- KHNZERYFIOUCKX-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ylmethyl 6-methoxy-1h-indole-3-carboxylate Chemical compound COC1=CC=C2C(C(=O)OCC34CCN(CC3)C4)=CNC2=C1 KHNZERYFIOUCKX-UHFFFAOYSA-N 0.000 claims 5
- GFXKYBZVBAFFEB-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 1h-indazole-3-carboxylate Chemical compound C1=CC=C2C(C(OCC34CCN(CC3)CC4)=O)=NNC2=C1 GFXKYBZVBAFFEB-UHFFFAOYSA-N 0.000 claims 5
- WCVKQCWPYGAONY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 2-methyl-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=C(C)NC2=CC=CC=C21 WCVKQCWPYGAONY-UHFFFAOYSA-N 0.000 claims 5
- VIMBZXPMHGSCMR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-(cyclopropylmethoxy)-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C(C1=C2)=CNC1=CC=C2OCC1CC1 VIMBZXPMHGSCMR-UHFFFAOYSA-N 0.000 claims 5
- PAUBQJDZIFBTBK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-(difluoromethoxy)-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(OC(F)F)C=C21 PAUBQJDZIFBTBK-UHFFFAOYSA-N 0.000 claims 5
- TUCUBBVRRKXMII-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-(trifluoromethoxymethyl)-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(COC(F)(F)F)C=C21 TUCUBBVRRKXMII-UHFFFAOYSA-N 0.000 claims 5
- CQPWZYTUOGSVFZ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-carbamoyl-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(C(=O)N)C=C21 CQPWZYTUOGSVFZ-UHFFFAOYSA-N 0.000 claims 5
- MDDRPRHJXXDKKV-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-chloro-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(Cl)C=C21 MDDRPRHJXXDKKV-UHFFFAOYSA-N 0.000 claims 5
- GCEPLXYEEIJUJZ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-cyano-1h-indole-3-carboxylate Chemical compound C1=C(C#N)C=C2C(C(OCC34CCN(CC3)CC4)=O)=CNC2=C1 GCEPLXYEEIJUJZ-UHFFFAOYSA-N 0.000 claims 5
- TVBLCSQOLNHLAF-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-methoxy-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(OC)C=C21 TVBLCSQOLNHLAF-UHFFFAOYSA-N 0.000 claims 5
- OHANUTMZXQOBOM-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-methoxy-2-methyl-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=C(C)NC2=CC=C(OC)C=C21 OHANUTMZXQOBOM-UHFFFAOYSA-N 0.000 claims 5
- OEIJNTVNSOQULQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 5-propan-2-yloxy-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC=C(OC(C)C)C=C21 OEIJNTVNSOQULQ-UHFFFAOYSA-N 0.000 claims 5
- GUKIAYZQCGKGEC-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 6-(difluoromethoxy)-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC(OC(F)F)=CC=C21 GUKIAYZQCGKGEC-UHFFFAOYSA-N 0.000 claims 5
- XIQPDIUHKIOZOL-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ylmethyl 6-methoxy-1h-indole-3-carboxylate Chemical compound C1CN(CC2)CCC12COC(=O)C1=CNC2=CC(OC)=CC=C21 XIQPDIUHKIOZOL-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- PKBVKBLTOFEJGO-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-1,2-benzothiazole-3-carboxamide Chemical compound C1=CC=C2C(C(NCC34CCN(CC3)CC4)=O)=NSC2=C1 PKBVKBLTOFEJGO-UHFFFAOYSA-N 0.000 claims 5
- IMRMDIBVFXYZFZ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(NCC34CCN(CC3)CC4)=O)=NNC2=C1 IMRMDIBVFXYZFZ-UHFFFAOYSA-N 0.000 claims 5
- CWKWTCNBOIXQKP-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(NCC34CCN(CC3)CC4)=O)=CNC2=C1 CWKWTCNBOIXQKP-UHFFFAOYSA-N 0.000 claims 5
- QAYPIHUQZWFFNR-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-5-fluoro-1h-indazole-3-carboxamide Chemical compound C1CN(CC2)CCC12CNC(=O)C1=NNC2=CC=C(F)C=C21 QAYPIHUQZWFFNR-UHFFFAOYSA-N 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 208000032841 Bulimia Diseases 0.000 claims 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 208000012661 Dyskinesia Diseases 0.000 claims 4
- 208000027534 Emotional disease Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 4
- 206010036631 Presenile dementia Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 206010039966 Senile dementia Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims 4
- 208000016620 Tourette disease Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 208000022531 anorexia Diseases 0.000 claims 4
- 231100000871 behavioral problem Toxicity 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- 208000030963 borderline personality disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001149 cognitive effect Effects 0.000 claims 4
- 231100000870 cognitive problem Toxicity 0.000 claims 4
- 206010061428 decreased appetite Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000037406 food intake Effects 0.000 claims 4
- 235000012631 food intake Nutrition 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 4
- 210000004558 lewy body Anatomy 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 230000036651 mood Effects 0.000 claims 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 4
- 230000005586 smoking cessation Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 230000029663 wound healing Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 206010020164 HIV infection CDC Group III Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000033464 Reiter syndrome Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 2
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 208000019664 bone resorption disease Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97672407P | 2007-10-01 | 2007-10-01 | |
| US60/976,724 | 2007-10-01 | ||
| PCT/US2008/078320 WO2009046025A1 (en) | 2007-10-01 | 2008-09-30 | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540562A JP2010540562A (ja) | 2010-12-24 |
| JP2010540562A5 true JP2010540562A5 (OSRAM) | 2011-11-17 |
| JP5022494B2 JP5022494B2 (ja) | 2012-09-12 |
Family
ID=40344599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527249A Expired - Fee Related JP5022494B2 (ja) | 2007-10-01 | 2008-09-30 | アルツハイマー病治療用のα７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン−４−イルメチル１Ｈ−インドール−３−カルボキシレート誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8114891B2 (OSRAM) |
| EP (1) | EP2217597B1 (OSRAM) |
| JP (1) | JP5022494B2 (OSRAM) |
| KR (1) | KR101565469B1 (OSRAM) |
| CN (2) | CN104193741B (OSRAM) |
| AT (1) | ATE503754T1 (OSRAM) |
| CA (1) | CA2701126A1 (OSRAM) |
| DE (1) | DE602008005928D1 (OSRAM) |
| DK (1) | DK2217597T3 (OSRAM) |
| ES (1) | ES2362326T3 (OSRAM) |
| MX (1) | MX2010003375A (OSRAM) |
| WO (1) | WO2009046025A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| SI2355822T1 (sl) | 2008-11-19 | 2013-02-28 | Envivo Pharmaceuticals, Inc. | Zdravljenje kognitivnih motenj z (R)-7-kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamidom in njegovimi farmacevtsko sprejemljivimi solmi |
| CN102802620A (zh) * | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| PE20130218A1 (es) | 2010-05-17 | 2013-03-20 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| US20130197028A1 (en) * | 2010-06-25 | 2013-08-01 | Oklahoma Medical Research Foundation | nAChRalpha7 Agonists and nAChRalpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD) |
| RU2014103474A (ru) * | 2011-07-01 | 2015-08-10 | Энвиво Фармасьютикалз, Инк. | Способы лечения умеренных когнитивных нарушений |
| US9309221B2 (en) * | 2012-04-10 | 2016-04-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1-substituted indazole derivative |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| JP6261048B2 (ja) * | 2012-12-05 | 2018-01-17 | 国立大学法人 新潟大学 | 破骨細胞が関与する疾患の予防又は治療剤 |
| WO2014149819A1 (en) | 2013-03-14 | 2014-09-25 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| EP3363800A1 (en) | 2013-10-03 | 2018-08-22 | Kura Oncology, Inc. | Heterocyclic inhibitors of erk and methods of use |
| CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| EP3114107B1 (en) | 2014-03-07 | 2020-07-22 | Recurium IP Holdings, LLC | Propellane derivates and synthesis |
| TW201617342A (zh) * | 2014-07-11 | 2016-05-16 | 阿法馬根公司 | 調節α７活性之啶類 |
| EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
| WO2017120532A1 (en) * | 2016-01-08 | 2017-07-13 | Alpharmagen, Llc | Polymorphs of a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1h-indole-3-carboxylate and uses thereof |
| US20190083460A1 (en) * | 2016-03-16 | 2019-03-21 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| EP3628043A4 (en) | 2017-05-15 | 2021-04-28 | Recurium IP Holdings, LLC | ANALGESIC COMPOUNDS |
| EP3520803A1 (en) * | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1223873A (en) | 1982-04-14 | 1987-07-07 | Francis D. King | Pharmaceutically active compounds |
| CH664567A5 (de) * | 1983-08-26 | 1988-03-15 | Sandoz Ag | Aromatische carbonsaeure- und sulfonsaeureester oder -amide. |
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| HU202108B (en) * | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| EP0350130A3 (en) | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
| IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| HU211081B (en) * | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| JPH04308950A (ja) | 1991-04-05 | 1992-10-30 | Nec Software Ltd | 通信メモリ管理装置 |
| GB9201751D0 (en) | 1992-01-28 | 1992-03-11 | Smithkline Beecham Plc | Compounds |
| US5190953A (en) * | 1992-03-26 | 1993-03-02 | A. H. Robins Company, Incorporated | Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents |
| US5300512A (en) * | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| JP3235913B2 (ja) * | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
| US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| AUPN862996A0 (en) | 1996-03-13 | 1996-04-04 | Fujisawa Pharmaceutical Co., Ltd. | A novel substituted-acetamide compound |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| EE04588B1 (et) | 1997-10-27 | 2006-02-15 | Neurosearch A/S | Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon |
| CA2333951C (en) | 1998-06-01 | 2012-02-28 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| DK1300407T4 (da) * | 2000-06-27 | 2011-09-05 | S A L V A T Lab Sa | Carbamater afledt af arylalkylaminer |
| AU2001284645A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001282873A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| JP2004506734A (ja) | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| ATE305468T1 (de) | 2000-12-22 | 2005-10-15 | Almirall Prodesfarma Ag | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten |
| CZ2005252A3 (cs) * | 2002-09-25 | 2005-11-16 | Memory Pharmaceuticals Corporation | Indazoly, benzothiazoly a benzoisothiazoly jejich příprava a použití |
| US7488737B2 (en) * | 2004-04-22 | 2009-02-10 | Memory Pharmaceutical Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| RU2418797C2 (ru) | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
-
2008
- 2008-09-30 AT AT08835512T patent/ATE503754T1/de active
- 2008-09-30 MX MX2010003375A patent/MX2010003375A/es active IP Right Grant
- 2008-09-30 ES ES08835512T patent/ES2362326T3/es active Active
- 2008-09-30 US US12/242,389 patent/US8114891B2/en not_active Expired - Fee Related
- 2008-09-30 CN CN201410331886.8A patent/CN104193741B/zh not_active Expired - Fee Related
- 2008-09-30 EP EP08835512A patent/EP2217597B1/en not_active Not-in-force
- 2008-09-30 WO PCT/US2008/078320 patent/WO2009046025A1/en not_active Ceased
- 2008-09-30 JP JP2010527249A patent/JP5022494B2/ja not_active Expired - Fee Related
- 2008-09-30 KR KR1020107008479A patent/KR101565469B1/ko not_active Expired - Fee Related
- 2008-09-30 CA CA2701126A patent/CA2701126A1/en not_active Abandoned
- 2008-09-30 DE DE602008005928T patent/DE602008005928D1/de active Active
- 2008-09-30 DK DK08835512.8T patent/DK2217597T3/da active
- 2008-09-30 CN CN2008801186316A patent/CN101883771A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540562A5 (OSRAM) | ||
| JP2019532079A5 (OSRAM) | ||
| JP5022494B2 (ja) | アルツハイマー病治療用のα７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン−４−イルメチル１Ｈ−インドール−３−カルボキシレート誘導体 | |
| JP2009507909A5 (OSRAM) | ||
| JP2008513516A5 (OSRAM) | ||
| JP2007522142A5 (OSRAM) | ||
| JP2017510643A5 (OSRAM) | ||
| JP2011517443A5 (OSRAM) | ||
| JP2020527588A5 (OSRAM) | ||
| JP2008513358A5 (OSRAM) | ||
| JP2004505078A5 (OSRAM) | ||
| CA2575874A1 (en) | Crystalline form of a biphenyl compound | |
| JP2013536833A5 (OSRAM) | ||
| JP2010508363A5 (OSRAM) | ||
| JP2013504593A5 (OSRAM) | ||
| WO2007141200A8 (en) | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases | |
| JP2010520264A5 (OSRAM) | ||
| JP2011530521A5 (OSRAM) | ||
| JP2005502680A5 (OSRAM) | ||
| JP2019513745A5 (OSRAM) | ||
| JP2008519818A5 (OSRAM) | ||
| AU2003284669A1 (en) | Isoindoline derivative | |
| JP2008511574A5 (OSRAM) | ||
| CN108290880B (zh) | 内酰胺类化合物衍生物及其应用 | |
| WO2013018371A1 (ja) | ビアリールエステル誘導体、及びそれを含む医薬 |